| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Introduction
This analysis examines the historical and forecast performance for Pfizer in
the ethical pharmaceutical sector. The profile encompasses global company
strategy, portfolio and pipeline analysis and assessment of financial
performance, with 1-6 year sales forecasts for key drugs. An interactive
forecasting and analysis tool provides continually updated quantitative and
qualitative information.
Key reasons to read this report
- Benchmark Pfizer's performance against key rivals in the ethical
pharmaceutical sector
- Assess how Pfizer's M&A driven growth strategy will continue to impact the
company's commercial performance out to 2013
- Analyze the impact of patent expiry for Pfizer's flagship product Lipitor,
which accounted for c.29% of the company's prescription drug sales in 2007
TABLE OF CONTENTS
Table of Contents
- CHAPTER 1 ABOUT THIS PROFILE
- Executive summary
- Quarterly news update
- Company introduction
- Company sales
- Company financials
- Key products and competitors
- Data sourcing
- Sales data
- Analyst consensus
- CHAPTER 2 EXECUTIVE SUMMARY
- Key findings
- Prescription pharmaceutical sales performance, 2001-13
- Financial performance, 2001-13
- Pfizer: PharmaVitae forecasts at a glance
- Strategic insight
- Introduction
- Pfizer pre-2001 - the Warner-Lambert acquisition
- Uptake of Lipitor - the blockbuster redefined
- Pfizer returns to the M&A trail - the Pharmacia acquisition
- Pfizer seeks to replicate Lipitor success with Cox-2franchise
- Lipitor - a double edged sword?
- Failure of Torcetrapib - No second chance for Lipitor
- What next for Pfizer?
- Internal revenue growth to prove insufficient
- Pfizer leads peer set into cost cutting territory
- In-licensing to remain a key opportunity
- Conclusions
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- CHAPTER 3 QUARTERLY NEWS UPDATE
- Product developments
- Deals and alliances
- Product deals
- Technology deals
- M&A activity
- Company announcements
- Future product milestones
- CHAPTER 4 COMPANY INTRODUCTION
- Key findings
- Background
- Key corporate developments
- M&A history & strategy
- CHAPTER 5 COMPANY SALES
- Key findings
- Prescription pharmaceutical sales and growth rate analysis, 2001-13
- Product analysis
- Product analysis, 2001-07
- Product analysis, 2007-13
- Therapy area analysis
- Therapy area analysis, 2001-07
- Therapy area analysis, 2007-13
- Therapy area focus, 2001-13
- Geographic analysis
- Geographic analysis, 2001-07
- Geographic analysis, 2007-13
- Geographic focus, 2001-13
- Launch/core/expiry analysis
- Explanation of launch/core/expiry analysis
- Launch analysis, 2007-13
- Core analysis, 2007-13
- Expiry analysis, 2007-13
- Launch/core/expiry configuration, 2007-13
- Molecule type analysis
- Molecule type analysis, 2001-07
- Molecule type analysis, 2007-13
- Externalization analysis
- Externalization analysis, 2001-07
- Externalization analysis, 2007-13
- CHAPTER 6 COMPANY FINANCIALS
- Key findings
- Reconciliation between PharmaVitae-formatted prescription pharma sales
and company-reported total sales, 2001-07
- Financial statements, 2001-07
- Profit and loss account, 2001-07
- Balance sheet, 2001-07
- Operating costs and profit analysis
- Operating costs and profit analysis, 2001-07
- Operating cost ratio and profit margin analysis, 2001-07
- Operating cost ratio and profit margin analysis, 2007-13
- Operating costs and profit analysis, 2007-13
- Return on capital employed analysis
- Capital employed analysis, 2001-07
- Return on capital employed (RoCE) analysis, 2001-07
- Market capitalization analysis
- Market capitalization analysis, 2001-07
- Total shareholder returns analysis, 2001-07
- CHAPTER 7 KEY PRODUCTS AND COMPETITORS
- Key findings
- Overview
- Cardiovascular
- Central Nervous System (CNS)
- Lyrica
- Chantix/Champix
- Zoloft
- Oncology
- Immunology & Inflammation
- Urology & gender specific health
- Infectious diseases
- Respiratory
- CHAPTER 8 APPENDIX
- R&D pipeline
- Abbreviations
- Exchange rates
- List of Tables
- Table 1: Pfizer - PharmaVitae forecasts at a glance
- Table 2: Pfizer key product developments, Q1 and Q2 2008
- Table 3: Pfizer product deals and alliances, Q1 and Q22008
- Table 4: Pfizer technology deals and alliances, Q1 andQ2 2008
- Table 5: Pfizer M&A activity, Q1 and Q2 2008
- Table 6: Pfizer company announcements, Q1 and Q2 2008
- Table 7: Pfizer future product milestones, 2008-10
- Table 8: Pfizer product portfolio overview ($m), 2001-07
- Table 9: Pfizer product portfolio overview ($m), 2007-13
- Table 10: Pfizer product portfolio overview ($m),2001-07
- Table 11: Pfizer product portfolio overview ($m),2007-13
- Table 12: Pfizer portfolio overview by geographic region($m), 2001-07
- Table 13: Pfizer portfolio overview by geographic region($m), 2007-13
- Table 14: Pfizer launch portfolio overview ($m), 2007-13
- Table 15: Pfizer core portfolio overview ($m), 2007-13
- Table 16: Pfizer expiry portfolio overview ($m), 2007-13
- Table 17: Pfizer portfolio overview by molecule type($m), 2001-07
- Table 18: Pfizer product portfolio overview by molecule type ($m), 2007-13
- Table 19: Pfizer product portfolio overview by source($m), 2001-07
- Table 20: Pfizer product portfolio overview by source($m), 2007-13
- Table 21: Total Pfizer sales by business unit ($m),2001-07
- Table 22: Pfizer profit and loss account ($m), 2001-07
- Table 23: Pfizer balance sheet ($m), 2001-07
- Table 24: Pfizer operating revenue/cost analysis ($m),2001-07
- Table 25: Pfizer operating cost ratio analysis (% of total revenues),
2001-07
- Table 26: Pfizer operating cost ratio analysis (% of total revenues),
2007-13
- Table 27: Pfizer operating revenue/cost analysis ($m),2007-13
- Table 28: Calculation of average 'other operating(expenditure)/income'
for Pfizer operating revenue/cost analysis ($m),2007-13
- Table 29: Pfizer capital employed ($m), 2001-07
- Table 30: Pfizer EBIT return on capital employed ($m),2001-07
- Table 31: Pfizer EBIT pre-tax return/Capital employed driver analysis
(%), 2001-07
- Table 32: Pfizer market capitalization ($ billion),2001-07
- Table 33: Pfizer total shareholder returns (annual %),2001-07
- Table 34: Key products overview
- Table 35: Lipitor: overview
- Table 36: Lipitor: sales forecast ($m), 2007-13
- Table 37: Norvasc: overview
- Table 38: Norvasc: sales forecast ($m), 2007-13
- Table 39: Lyrica: overview
- Table 40: Lyrica: sales forecast ($m), 2007-13
- Table 41: Chantix/Champix: overview
- Table 42: Chantix/Champix: sales forecast ($m), 2007-13
- Table 43: Zoloft: overview
- Table 44: Zoloft: sales forecast ($m), 2007-13
- Table 45: Sutent: overview
- Table 46: Sutent: sales forecast ($m), 2007-13
- Table 47: Celebrex: overview
- Table 48: Celebrex: sales forecast ($m), 2007-13
- Table 49: Viagra: overview
- Table 50: Viagra: sales forecast ($m), 2007-13
- Table 51: Detrol/Detrol LA: overview
- Table 52: Detrol/Detrol LA: sales forecast ($m), 2007-13
- Table 53: Vfend: overview
- Table 54: Vfend: sales forecast ($m), 2007-13
- Table 55: Zyvox: overview
- Table 56: Zyvox: sales forecast ($m), 2007-13
- Table 57: Selzentry: overview
- Table 58: Selzentry: sales forecast ($m), 2007-13
- Table 59: Zyrtec/Zyrtec D: overview
- Table 60: Zyrtec/Zyrtec D: sales forecast ($m), 2007-13
- Table 61: Pfizer's R&D pipeline (PhaseI-registration)
- Table 62: Exchange rates, 2007
- List of Figures
- Figure 1: Pfizer prescription pharmaceutical performance, sales ($m) and
growth rate (%), 2001-13
- Figure 2: Pfizer's financial performance ($m), 2001-13
- Figure 3: Pfizer prescription pharmaceutical sales byM&A activity
($m), 2001-13
- Figure 4: Lipitor sales as a percentage of Pfizer prescription
pharmaceutical sales ($m), 2001-13
- Figure 5: Reduction in SG&A costs to drive only temporary growth in
operating profit
- Figure 6: Pfizer SWOT analysis
- Figure 7: Pfizer prescription pharmaceutical performance, sales ($m) and
growth rate (%), 2001-13
- Figure 8: Pfizer key sales growth driver & resistors($m), 2001-07
- Figure 9: Pfizer key sales growth drivers & resistors ($m), 2007-13
- Figure 10: Pfizer prescription pharmaceutical sales by therapy area ($m),
2001-13
- Figure 11: Pfizer prescription pharma sales by therapy area (% of total),
2001-13
- Figure 12: Pfizer prescription pharmaceutical sales by geographic region
($m), 2001-13
- Figure 13: Pfizer growth drivers and resistors by geographic region ($m),
2001-07
- Figure 14: Pfizer drivers and resistors by geographic region ($m), 2007-13
- Figure 15: Pfizer prescription pharmaceutical sales by geographic region
(% of total), 2001-13
- Figure 16: Pfizer launch/core/expiry configuration ($m),2007-13
- Figure 17: Pfizer prescription pharmaceutical sales by molecule type
($m), 2001-13
- Figure 18: Pfizer growth drivers and resistors by molecule type ($m),
2007-13
- Figure 19: Pfizer prescription pharmaceutical sales by source ($m),
2001-13
- Figure 20: Pfizer growth drivers and resistors by source($m), 2001-07
- Figure 21: Pfizer growth drivers and resistors by source($m), 2007-13
- Figure 22: Pfizer operating revenue/cost analysis ($m),2001-13
- Figure 23: Pfizer operating cost ratio analysis (% of total revenues),
2001-13
- Figure 24: Pfizer return on capital employed, EBIT margin and capital
turnover, 2001-07
- Figure 25: Return on capital employed formula
- Figure 26: Pfizer market capitalization ($ billion),2001-07
- Figure 27: Pfizer total shareholder returns vs. S&P500 ($m), 2001-07
|
